Last reviewed · How we verify

AM-Pharma — Portfolio Competitive Intelligence Brief

AM-Pharma pipeline: 1 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
recAP recAP marketed Recombinant enzyme Lipopolysaccharide (LPS) and pathogen-associated molecular patterns (PAMPs) Immunology / Gastroenterology / Critical Care

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AO GENERIUM · 1 shared drug class
  2. Fondation Ophtalmologique Adolphe de Rothschild · 1 shared drug class
  3. Protalix · 1 shared drug class
  4. The Hospital for Sick Children · 1 shared drug class
  5. University Hospital, Strasbourg, France · 1 shared drug class
  6. University of Jena · 1 shared drug class
  7. University of Missouri-Columbia · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for AM-Pharma:

Cite this brief

Drug Landscape (2026). AM-Pharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/am-pharma. Accessed 2026-05-14.

Related